Biktarvy and Pathological fracture - a phase IV clinical study of FDA data

Summary:

Pathological fracture is reported as a side effect among people who take Biktarvy (bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate), especially for people who are male, 50-59 old, also take Truvada, and have Acquired immunodeficiency syndrome.

The phase IV clinical study analyzes which people have Pathological fracture when taking Biktarvy. It is created by eHealthMe based on reports of 19,474 people who have side effects when taking Biktarvy from the FDA, and is updated regularly.

What is Biktarvy?

Biktarvy has active ingredients of bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate. It is often used in hiv infection. eHealthMe is studying from 19,543 Biktarvy users. Check the latest studies of Biktarvy.

What is Pathological fracture?

Pathological fracture (broken bone caused by disease) is found to be associated with 833 drugs and 542 conditions by eHealthMe. Check the latest studies of Pathological fracture.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 04, 2026

19,474 people reported to have side effects when taking Biktarvy.
Among them, 38 people (0.2%) have Pathological fracture.

$Could Biktarvy cause Pathological fracture?$

Among these 38 people:

What is the gender of people who have Pathological fracture when taking Biktarvy? *

female: 23.68 %
male: 76.32 %

What is the age of people who have Pathological fracture when taking Biktarvy? *

What are other drugs people take besides Biktarvy? *

What are other side effects people have besides Pathological fracture? *

Bone Density Decreased: 31 people, 81.58%
Osteoporosis (bones weak and more likely to break): 27 people, 71.05%
Bone Loss: 22 people, 57.89%
Aseptic Necrosis (the death of bone tissue due to a lack of blood supply): 20 people, 52.63%
Chronic Kidney Disease: 17 people, 44.74%
Acute Kidney Failure: 16 people, 42.11%
Tooth Loss: 15 people, 39.47%
Emotional Distress: 13 people, 34.21%
Stress And Anxiety: 13 people, 34.21%
Pain: 13 people, 34.21%

What are the existing conditions these people have? *

Acquired Immunodeficiency Syndrome (disease of the human immune system caused by the human immunodeficiency virus (hiv)): 1 person, 2.63%

* Approximation only. Some reports may have incomplete information.

Do you take Biktarvy and have Pathological fracture?

- Check whether Pathological fracture is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Biktarvy:

Biktarvy (19,543 reports)

Pathological fracture treatments and more:

Pathological fracture (7,718 reports)

How severe was Pathological fracture and when was it recovered:

Pathological fracture in Biktarvy

Expand to all the drugs that have ingredients of bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate:

Pathological fracture and drugs with ingredients of bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Biktarvy:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Pathological fracture:

Pathological fracture (833 drugs)

Browse all the conditions that are associated with Pathological fracture:

Pathological fracture (542 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate (the active ingredients of Biktarvy) and Biktarvy (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.